Myeloproliferative neoplasm physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Patients with myeloproliferative neoplasm are usually well-appearing. Physical examination of patients with chronic myelogenous leukemia is usually remarkable for skin bruising, fever, splenomegaly, and lymphadenopathy.

Physical Examination

Common physical examination findings associated with myeloproliferative neoplasm include:^[1]^[2]^[3]^[4]

Appearance of the Patient

Patients are usually well-appearing at an early time point in the disease and ill-appearing at a later time point in the disease.

Vital Signs

Skin

HEENT

Decreased vision acuity
Mucosal pallor

Neck

Lymphadenopathy

Lungs

Vesicular breath sounds
Wheezing

Chest

Axillary lymphadenopathy (usually painless)

Abdomen

Splenomegaly
Hepatomegaly
Tenderness to palpation

Genitourinary

Inguinal lymphadenopathy (usually painless)
Scrotal swelling
Priapism

References

↑ Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). “Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia”. Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.
↑ Tefferi A (2006). “Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era”. Hematology Am Soc Hematol Educ Program: 240–245. PMID 17124067.
↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/signs-and-symptoms/?region=ab
↑ Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC; et al. (2012). “Philadelphia-negative chronic myeloproliferative neoplasms”. Rev Bras Hematol Hemoter. 34 (2): 140–9. doi:10.5581/1516-8484.20120034. PMC 3459391. PMID 23049404.

Template:WH Template:WS

[pmid25810569-1] Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). “Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia”. Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.

[Tefferi-2] Tefferi A (2006). “Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era”. Hematology Am Soc Hematol Educ Program: 240–245. PMID 17124067.

[cancer.ca-3] Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/signs-and-symptoms/?region=ab

[pmid23049404-4] Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC; et al. (2012). “Philadelphia-negative chronic myeloproliferative neoplasms”. Rev Bras Hematol Hemoter. 34 (2): 140–9. doi:10.5581/1516-8484.20120034. PMC 3459391. PMID 23049404.

[1]

[2]

[3]

[4]